J&J Makes Cuts In Bid To Strengthen Ailing Medtech Business
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is cutting 4% to 6% of its global medical device business workforce in an effort to turn around weak performance. The cuts will come from its orthopedics, surgery and cardiovascular units, but the proportion of reductions per business and details on which product segments J&J might be looking to drop altogether were not disclosed.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.